Merrimack Pharmaceuticals Inc. (MACK)
Merrimack Pharmaceuticals Statistics
Share Statistics
Merrimack Pharmaceuticals has 14.79M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 14.79M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 9.66M |
| Failed to Deliver (FTD) Shares | 278.24K |
| FTD / Avg. Volume | 152.35% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -162.36 and the forward PE ratio is null. Merrimack Pharmaceuticals's PEG ratio is 6.52.
| PE Ratio | -162.36 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 10.23 |
| P/FCF Ratio | -125.99 |
| PEG Ratio | 6.52 |
Enterprise Valuation
Merrimack Pharmaceuticals has an Enterprise Value (EV) of 185.76M.
| EV / Sales | 0 |
| EV / EBITDA | -85.37 |
| EV / EBIT | -122.05 |
| EV / FCF | -122.05 |
Financial Position
The company has a current ratio of 43.5, with a Debt / Equity ratio of 0.
| Current Ratio | 43.5 |
| Quick Ratio | 43.5 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -6.3% and Return on Invested Capital is -11.73%.
| Return on Equity | -6.3% |
| Return on Assets | -6.15% |
| Return on Invested Capital | -11.73% |
| Revenue Per Employee | $- |
| Profits Per Employee | $- |
| Employee Count | 0 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 12K |
| Effective Tax Rate | -1.03% |
Stock Price Statistics
The stock price has increased by 2.92% in the last 52 weeks. The beta is 1.42, so Merrimack Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.42 |
| 52-Week Price Change | 2.92% |
| 50-Day Moving Average | 14.86 |
| 200-Day Moving Average | 13.46 |
| Relative Strength Index (RSI) | 78.97 |
| Average Volume (20 Days) | 182.63K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -2.18M |
| Net Income | -1.18M |
| EBITDA | -2.18M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.08 |
Balance Sheet
The company has 5.99M in cash and 0 in debt, giving a net cash position of 5.99M.
| Cash & Cash Equivalents | 5.99M |
| Total Debt | 0 |
| Net Cash | 5.99M |
| Retained Earnings | -548.82M |
| Total Assets | 244.32M |
| Working Capital | 221.65M |
Cash Flow
In the last 12 months, operating cash flow was -1.52M and capital expenditures 0, giving a free cash flow of -1.52M.
| Operating Cash Flow | -1.52M |
| Capital Expenditures | 0 |
| Free Cash Flow | -1.52M |
| FCF Per Share | -0.11 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MACK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.62% |
| FCF Yield | -0.79% |
Analyst Forecast
Currently there are no analyst rating for MACK.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Sep 6, 2019. It was a forward split with a ratio of 1271:1000.
| Last Split Date | Sep 6, 2019 |
| Split Type | forward |
| Split Ratio | 1271:1000 |
Scores
| Altman Z-Score | 4.99 |
| Piotroski F-Score | 2 |